Starling Oncology, Inc.

Starling Oncology, Inc., trading on Nasdaq under the ticker TOI, filed an 8-K with the Securities and Exchange Commission on September 2, 2026 (accession number 0001079973-26-001208). The company operates in the healthcare sector with a focus on oncology services and traces its public-market origins to a SPAC merger involving DFB Healthcare Acquisitions Corp II, which completed its business combination in 2021, bringing the predecessor oncology enterprise to public markets. The 8-K disclosure reflects the company's ongoing reporting obligations as a public registrant in the specialty healthcare and cancer-care services space. For complete filing history, sponsor details, and real-time SPAC analytics on TOI and hundreds of other vehicles, create a free account at SpacDesk.